SCHEMBL1886286

SCHEMBL1886286

Cc1cccc(-c2nc3c(C)cccc3cc2CO)c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 9/20 0.54
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ATM Q13315 1/20 0.40
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
DPP4 P27487 1/20 0.37
MAP2K4 P45985 1/20 0.36
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
NR4A2 P43354 1/20 0.36
RXRG P48443 1/20 0.36
RAB9A P51151 1/20 0.36
MAPK14 Q16539 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1887862 0.88 MEN1 (0.48) PIK3CDMEN1KMT2AATMDRD4
SCHEMBL1879223 0.87 MEN1 (0.47) PIK3CDMEN1KMT2AATMDRD4
SCHEMBL1877014 0.86 PIK3CD (0.54) PIK3CDATMDRD4DRD3L3MBTL1
SCHEMBL1879180 0.84 PIK3CD (0.57) PIK3CDMEN1KMT2A
SCHEMBL1883994 0.82 KDM4E (0.49) PIK3CDMEN1KMT2AL3MBTL1RAB9A
SCHEMBL1878618 0.82 ATM (0.52) PIK3CDMEN1KMT2AATMDRD4
SCHEMBL1878979 0.80 MEN1 (0.43) PIK3CDMEN1KMT2AATMDRD4
SCHEMBL1887556 0.79 PIK3CD (0.53) PIK3CDMEN1KMT2AATMDRD4
SCHEMBL1883927 0.79 MEN1 (0.42) PIK3CDMEN1KMT2AATMDRD4
SCHEMBL1883842 0.78 MEN1 (0.41) PIK3CDMEN1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399483-B2 Quinoxaline and quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2013-03-19 US disclosed
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA, S.A. (BE) 2011-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS PDXK, PDPK1, PIKFYVE PIK3CD 8/4885MEN1 1813/4885KMT2A 1617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.